Research Models

A7 APP transgenic


Back to the Top

Species: Mouse
Genes: APP
Mutations: APP K670_M671delinsNL (Swedish), APP T714I (Austrian)
Modification: APP: Transgenic
Disease Relevance: Alzheimer's Disease
Strain Name: N/A
Genetic Background: C57BL/6J
Availability: Unknown


This APP transgenic overexpresses mutant human APP under the control of the Thy-1.2 promoter, driving neuronal expression. The transgene carries two mutations associated with familial Alzheimer’s disease: the Swedish double mutation (K670N/M671L) and the Austrian mutation (T714I). The expression level of human APP was reported as approximately 1.4-fold endogenous APP (Yamada et al., 2009).

These mice develop progressive amyloid deposition in the cerebral cortex at approximately at 9-12 months of age. By 21 months amyloid pathology is extensive.

The A7 line was used to investigate the effects of chronic optogenetic stimulation on Aβ production and amyloid plaque development. Neuronal hyperexcitability in the hippocampus increased interstitial Aβ42 and plaque burden in the projection area of the perforant pathway. Light stimulation in the optogenetically altered animals also elicited seizures. Seizures were not observed in the absence of optogenetic stimulation (Yamamoto et al., 2015).

Modification Details

The transgene expressed by these mice encodes mutant APP with the Swedish mutation (K670N/M671L) and the Austrian mutation (T714I) under the control of the Thy1.2 promoter.

Phenotype Characterization

When visualized, these models will distributed over a 18 month timeline demarcated at the following intervals: 1mo, 3mo, 6mo, 9mo, 12mo, 15mo, 18mo+.


No Data

  • Tangles
  • Neuronal Loss
  • Gliosis
  • Synaptic Loss
  • Changes in LTP/LTD
  • Cognitive Impairment


These mice develop progressive amyloid deposition in the cerebral cortex by 9-12 months. By 21 months of age amyloid pathology is extensive.


No data.

Neuronal Loss

No data.


No data.

Synaptic Loss

No data.

Changes in LTP/LTD

No data.

Cognitive Impairment

No data.

Last Updated: 06 Apr 2022


No Available Comments

Make a comment or submit a question

To make a comment you must login or register.


Paper Citations

  1. . Abeta immunotherapy: intracerebral sequestration of Abeta by an anti-Abeta monoclonal antibody 266 with high affinity to soluble Abeta. J Neurosci. 2009 Sep 9;29(36):11393-8. PubMed.
  2. . Chronic optogenetic activation augments aβ pathology in a mouse model of Alzheimer disease. Cell Rep. 2015 May 12;11(6):859-65. Epub 2015 Apr 30 PubMed.

Further Reading


  1. . BACE1 activity is modulated by cell-associated sphingosine-1-phosphate. J Neurosci. 2011 May 4;31(18):6850-7. PubMed.